Telemedicine – the standalone study that became the new normal
Dr Vijay Prabhakar tells us how a remote healing project made him a pandemic pioneer.Read it now!
Search
Breaking prejudice in lung cancer
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
On the road with sanitation workers in India
Exhaust fumes, heat, work and traffic accidents. Overcoming all these odds, the sanitation workers in India fight a daily battle.
collaboration criving innovation
In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
The first liquid solution for hypertension in cats
Boehringer Ingelheim launches Semintra® 10 mg/ml Oral Solution in selected European countries for the treatment of feline hypertension.
Could decentralised trials transform the way we view depression?
Could decentralised trials transform the way we view depression? Dr Vikas Mohan Sharma believes this could deliver meaningful changes for patients all arround.
Stroke Prevention in AF
Stroke Prevention in AF
“My ultimate goal is to cure cancer”
Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.
Driving environmental solutions for people and planet
In 2022, Boehringer Ingelheim's MORE GREEN environmental sustainability initiative has reached new milestones driving our global decarbonization efforts
Nurjanahs Story
Nurjanah went from a sporty young woman to someone who no longer had the energy to do simple, everyday tasks. She was diagnosed with scleroderma.
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
TwistPak Mixing platform for swine vaccines
TwistPak® allows for fresh mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® on farm in less than 5 seconds
Launch of first veterinary vaccines produced in China
Swine vaccine Ingelvac PRRS MLV, produced by Boheringer Ingelheim veterinary vaccine manufacturing plant in Taizhou is now officially supplied to the China market.
collaboration-LIBD
Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
BI_PharmAccess_launch_digital_healthcare_program
Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
12th Expert Forum on Farm Animal Well-Being
The 12th Expert Forum on Farm Animal Well-Being brought together over 100 industry experts
FOYA_Shanghai
Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”
Cystic Fibrosis Genetherapy Development Option Excercise
Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
Embracing diversity in clinical trials
At Boehringer Ingelheim, we understand the crucial need of embracing diversity in clinical trials as an opportunity to enable more equitable healthcare.
Boehringer Ingelheim strong growth pipeline acceleration 2023
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
On the path to decarbonization: How we reduce our emissions
How our sites Fornovo and Paulínia became carbon-neutral and support our recently SBTi-validated 2030 goals
Circular economy: Taking action to reduce plastic waste
The packaging department team at Yamagata, Japan, managed to reduce their waste plastic material for a greener and more sustainable tomorrow
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia